Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Grants to Eurofarma Exclusive Rights for Obesity Agent Lorcaserin in Brazil
December 18, 2018
- Efficacy of Fentos Tape for Cancer Pain in Opioid-Naïve Patients Confirmed in PIII Study: Hisamitsu
December 17, 2018
- Janssen Applies for Darzalex for Previously Untreated Multiple Myeloma Patients
December 17, 2018
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
December 17, 2018
- Lundbeck Japan to Quadruple Workforce by Next Summer, Eyes Vortioxetine Launch: Chief
December 14, 2018
- Astellas CEO Sees Cell Therapy Biz Model Established by “around 2030”
December 14, 2018
- ASKA to Review 5-Year Biz Plan after Hit by NHI Price Cut, Despite New Drug Launches
December 14, 2018
- Daiichi Sankyo Mulling Moving Up DS-8201 Filing to FY2019: Oncology Chief
December 13, 2018
- Ethical Drug Sales Up 2.0% in October: Crecon
December 13, 2018
- Otsuka’s US Subsidiary Pulls Plug on License Deal to Sumatriptan Nasal Spray for Acute Migraine
December 13, 2018
- Eisai, Takeda to Provide Compound Libraries to GARDP for Development of New Antibiotics
December 13, 2018
- Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
December 12, 2018
- Astellas FLT3 Inhibitor Xospata Now Available in US
December 12, 2018
- Daiichi Sankyo, Sarah Cannon Ink Cancer Collaboration, DS-7300 Trial to Get Underway in FY2019
December 12, 2018
- Ribomic Hooks Up with US Research Consortium on FGF Aptamer Therapeutics
December 12, 2018
- Mitsubishi Tanabe Links Up with Chinese Biopharma to Streamline Search for Seed Compounds
December 12, 2018
- DS-8201 Yields 44.2% ORR in HER2-Low Breast Cancer: Daiichi Sankyo
December 11, 2018
- Avastin Top-Seller Drug in Japan for 4 Months Running: Encise Snapshot
December 11, 2018
- Pfizer Marks Foray into Japan Biosimilar Market with Remicade Follow-On
December 11, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…